In Plain English:
Mod GRF 1-29 is a lab-stabilised copy of the first 29 amino acids of growth hormone-releasing hormone (GHRH) — the signal your hypothalamus fires at the pituitary to trigger a GH burst. Four amino acid swaps block the enzymes that would normally destroy GHRH within seconds, extending active life to roughly 30 minutes while keeping the natural somatostatin brake intact so GH cannot overshoot. Each injection produces one clean, physiological GH pulse. Because the pulse is brief and the peptide carries no albumin-binding hook (DAC), you control timing precisely — commonly paired with a GHRP such as Ipamorelin pre-bed or post-workout to amplify the magnitude of each release event.
Research Maturity
Limited Human (34 PubMed results (CJC-1295 / mod GRF); 2 human RCTs but No DAC variant not independently trialled+ Studies)
Focus
Body Composition
Hormone Signaling
Recovery Support
Origin
Developed by ConjuChem Biotechnologies (Montreal, early 2000s) as the tetrasubstituted scaffold underlying CJC-1295 DAC, before the albumin-binding maleimide linker was added. The four substitutions — D-Ala at position 2 (DPP-IV resistance), Gln at position 8 (deamidation block), Ala at position 15 (rigidity), Leu at position 27 (oxidation resistance) — together stabilise GHRH(1-29) against plasma proteases while preserving full GHRHR agonism. Identified alongside CJC-1295 in the 2005 ConjuChem albumin-conjugate study (PMID 15817669). No DAC variant reached independent IND or Phase I filing; studied as the active backbone comparator in CJC-1295 pharmacology work.
Mechanism
Full agonist at GHRH receptor (GHRHR) on anterior pituitary somatotrophs. Receptor engagement couples to Gs protein, activating adenylyl cyclase and raising intracellular cAMP, which activates PKA. PKA phosphorylates downstream effectors driving GH gene transcription and stimulates calcium influx through voltage-gated channels, triggering exocytosis of stored GH vesicles. Somatostatin feedback pathway remains completely intact — each pulse self-terminates and cannot produce sustained non-physiological GH elevation without repeated injections. Downstream: pulsatile GH elevations drive hepatic IGF-1 synthesis, which mediates anabolic and lipolytic effects. D-Ala2 substitution blocks DPP-IV cleavage at the Ala2-Ile3 bond, the primary inactivation site of native GHRH; Gln8 blocks asparagine rearrangement to aspartate (deamidation); Ala15 stabilises helical backbone geometry; Leu27 eliminates methionine sulfoxide formation.
Outcome
Pulsatile serum GH rise (peak ~10-20 min post-injection); downstream hepatic IGF-1 elevation; lean body mass accrual (significant in male models, attenuated in females); subcutaneous fat reduction; improved sleep architecture (slow-wave and REM); muscular contractile force; skin collagen deposition; muscle growth velocity (+74% in one preclinical model over 1 year). Typically dosed 1-3x daily; effects are injection-timed rather than sustained.
